TEMPE, Ariz., Dec. 2 /PRNewswire-FirstCall/ -- OrthoLogic Corp. announced today that management will provide an overview of the Company and its lead compound for tissue and bone healing, Chrysalin(R), at the First Albany Capital Annual Growth Conference. The presentation will be delivered at 12:00 p.m. EST on Wednesday, December 7, 2005 at The Mandarin Oriental hotel in New York.
The presentation will be webcast live and may be accessed by visiting the Investors section of the Company’s website, www.orthologic.com. It will be archived for 30 days.
OrthoLogic is a biotechnology company focused on the development and commercialization of the novel synthetic peptide Chrysalin(R) (TP508) in three lead indications, all of which represent areas of significant unmet medical need -- fracture repair, diabetic foot ulcer healing and cartilage defect repair. Based on the Company’s pioneering scientific research of the natural healing cascade, OrthoLogic has become the leading company focused on tissue and bone repair. OrthoLogic is committed to developing a pipeline of novel peptides and other molecules aimed at helping patients with equally under-served conditions. The Company maintains exclusive worldwide rights for Chrysalin. OrthoLogic’s corporate headquarters are in Tempe, Arizona. For more information, please visit the Company’s website: www.orthologic.com.
OrthoLogic Corp.
CONTACT: Media, Lauren Tortorete of Biosector 2, +1-212-845-5609; orInvestors, Melanie Friedman of Stern Investor Relations, +1-212-362-1200,for OrthoLogic Corp.
Web site: http://www.orthologic.com/
